

Congratulations to the recipients of the 2024 Emerging Investigator Awards! These early career investigators are recognized for their contribution of outstanding abstracts to each abstract category.

Antiphospholipid Syndrome Category

0839. Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity

**Haoyu Pan**

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Category

0776. Follicular Dendritic Cell PD-L1 Expression Promotes Autoreactive Germinal Center Formation

**Elliot Akama-Garren, PhD, MSc**

Cytokines & Cell Trafficking Category

2596. Clock Gene Bmal1 Contributes to Inflammation via Phosphorylation of NF- $\kappa$ B/p65 in RA-FLS

**Hikari Tsukamoto, MSc**

Epidemiology & Public Health Category

0846. Three Novel Metabolomic Signatures of Inflammation for Female Gout Risk: A Prospective Cohort Study over 26 Years

**Sharan Rai, PhD**

Genetics, Genomics & Proteomics Category

2533. Genome-wide Association of Rheumatoid Arthritis in the African Ancestry Identifies HLA Amino Acid Polymorphisms of Risk

**Harrison Zhang, BA**

Health Services Research Category

2610. Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial

**Johannes Knitza, MD**

Healthcare Disparities in Rheumatology Category

2552. Changes in Social Determinants of Health Needs Uncovered by a Rheumatology-Based Screening and Assistance Program

**Haelynn Gim, BA**

Imaging of Rheumatic Diseases Category

0850. Assessment of Correlation Between Composite Ultrasonographic Index (ECODAS) and Disease Activity Score 28 in Patients with Rheumatoid Arthritis

**Komal Verma Saluja, MBBS**

Immunological Complications of Therapy Category

1730. Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors

**Daniel Portnoy, BS**

Infection-related Rheumatic Disease Category

2611. Continuation versus Temporary Interruption of Immunomodulatory Agents in Case of an Infection in IRD Patients: Results of a Randomized Controlled Trial

**Merel Opdam, MD**

Innate Immunity Category

1702. Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss

**Yunwei Xia, BA**

Measures & Measurement of Healthcare Quality Category

2529. Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project

**Dori Abel, MD, MS**

Metabolic & Crystal Arthropathies – Basic & Clinical Science Category

0271. Intercritical Gout Represents a Systemic Inflammatory State

**Tanner Ourada, BS**

Miscellaneous Rheumatic & Inflammatory Diseases Category

0855. Addition of Immunosuppressive Agents And/or Intravenous Immunoglobulin to Steroids in the Treatment of Susac Syndrome: A National Cohort Study

**Alexandra Kachaner, MD**

Muscle Biology, Myositis, & Myopathies Category

2667. Anti-Mi2 Autoantibodies in Dermatomyositis Patients Also Recognize Autoimmune Regulator (AIRE) Protein

**Jon Musai, BS**

ARP Clinical Practice/Patient Care Category

2655. Diagnostic Challenges of Dermatomyositis: A Retrospective Study of Its Dermatologic Mimics and Misdiagnoses

**Aaron Bao, MD**

ARP Orthopedics, Low Back Pain, & Rehabilitation Category

1666. Preliminary Effects of a Fully-Remote Online Physical Activity Program Following Knee Replacement

**Scott Jamieson, MS**

Orthopedics, Low Back Pain, & Rehabilitation Category

1171. Differences in Microbiome Profiles Based on Pain Severity and Inflammatory Biomarkers in Acute Low Back Pain

**Rebecca Fillipo, PT, DPT**

Osteoarthritis – Clinical Category

0864. Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study

**Kristine Godziuk, PhD**

Osteoarthritis & Joint Biology – Basic Science Category

1657. Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis

**Marie Binvignat, MD**

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Category

2566. Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study

**Andriko Palmowski, MD**

Pain in Rheumatic Disease Including Fibromyalgia Category

0794. Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup

**Shreena Kamlesh Gandhi, MD, MBBS**

Patient Outcomes, Preferences, & Attitudes Category

1672. The Evaluation of SLE Outcome Measures in Telemedicine

**Maya Souvignier, BA**

Pediatric Rheumatology – Basic Science Category

0832. Spatial Transcriptomic Assessment of Histologically Damaged and Unaffected Glomeruli in Class III Pediatric Lupus Nephritis Reveals Distinct Transcriptional Programs

**Sarah McCuaig, MD, PhD**

Pediatric Rheumatology – Clinical Category

2625. Brain Injury Markers Correlate with Impaired Executive Function and Disease Activity in Children with Systemic Lupus Erythematosus

**Oscar Mwizerwa, MBBS, MMed**

Professional Education Category

1737. RheumMadness 2024: The Practical Impact of the Practically Perfect Season

**Eric Wilson, MD**

RA – Etiology & Pathogenesis Category

0056. Association of Soluble Immune Checkpoint Proteins with the Risk of Developing RA in ACPA-positive At-risk Individuals

**Ryo Motoyama, MD**

Reproductive Issues in Rheumatic Disorders Category

0806. Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events

**Leah K. Flatman, BSc, MSc**

Rheumatoid Arthritis – Animal Models Category

2542. Group 2 Innate Lymphoid Cells Aggravates Development of Inflammatory Arthritis

**Anders Nguyen, MSc**

Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes Category

0804. Serologic and Clinical Predictors of Progressive Pulmonary Fibrosis in Rheumatoid Arthritis-associated Interstitial Lung Disease Progression: A Prospective Longitudinal Cohort

**Sung Hae Chang, MD, PhD, MPH**

Rheumatoid Arthritis – Etiology & Pathogenesis Category

0771. Arid5b Controls Pathologic Inflammatory versus Invasive Fibroblast Behavior

**Angela Zou, BSc, MSc**

Rheumatoid Arthritis – Treatments Category

2672. Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial

**Quirine Dumoulin, MD, MSc**

Sjögren's Syndrome – Basic & Clinical Science Category

2632. Genetically-engineered Ro-specific Regulatory T Cells to Treat Primary Sjögren's Disease

**Zhi Feng Sherman Lim, PhD**

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Category

1707. TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease

**Stephanie Glavaris, PhD**

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Category

0772. Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis

**Andreas Kerschbaumer, MD, PhD**

Spondyloarthritis Including Psoriatic Arthritis – Treatment Category

0599. Sex-related Differences in Efficacy of Biologics in Axial Spondyloarthritis: A Systematic Review and Meta-analysis

**Haseeb Chaudhary, MD**

Systemic Lupus Erythematosus – Animal Models Category

1646. A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE

**Iolanda Miceli, BmedSci**

Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Category

1683. 68Ga-FAPI PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis

**Hui Shi, MD, PhD**

Systemic Lupus Erythematosus – Etiology & Pathogenesis Category

2599. Xist Deletion in B Cells Results in Systemic Lupus Erythematosus Phenotypes

**Claudia Lovell, BA**

Systemic Lupus Erythematosus – Treatment Category

1751. Precision Targeting of Autoreactive 9G4 B Cells in Systemic Lupus Erythematosus Using Engineered Chimeric Antigen Receptor (CAR)- and Chimeric T Cell Receptor (cTCR)-T Cells

**Jin Liu, PhD, MBBS**

Systemic Sclerosis & Related Disorders – Basic Science Category

1643. Single Nuclei Multiome and Spatial Transcriptomic Analysis of Early, Untreated SSc Skin Identifies Signaling Interactions Between Macrophages and Fibroblasts

**Helen Jarnagin, BA**

Systemic Sclerosis & Related Disorders – Clinical Category

1690. FAPI-PET/CT as a Predictor of Accelerated Lung Function Deterioration in Systemic Sclerosis Related Interstitial Lung Disease (ILD): Preliminary-interim Analysis from a Confirmatory Risk Factor Study

**Christina Bergmann, MD**

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Category

1853. Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome

**Leah Huey, BS**

Vasculitis – ANCA-Associated Category

0824. The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with ENT Manifestations of ANCA-Associated Vasculitis (AAV): Post Hoc Analysis of Subset of Patients Recruited to the PROTECT-V Trial

**Benjamin Lim, MBChB**

Vasculitis – Non-ANCA-Associated & Related Disorders Category

1696. Comparison of Mycophenolate Mofetil Plus Methotrexate versus Cyclophosphamide with Sequential Azathioprine for Active Takayasu's Arteritis: An Open-Label, Randomized-Controlled Trial

**Xiaochuan Sun, MD**